Castleman's disease

Castleman's disease may be divided into four types.

There is no standard therapy for multicentric Castleman's disease.

This disorder is a complication of cancer, usually lymphoma and Castleman's disease.

Unicentric Castleman's disease involves tissue growths at only a single site.

Eran Almog lived in the village until his death from Castleman's disease.

There are several variants of Castleman's disease.

Examples include Castleman's disease and lymphedema.

Clinical studies for Castleman's disease and systemic juvenile idiopathic arthritis started in 2001 and 2002, respectively.

In June 2005, tocilizumab was approved in Japan for Castleman's disease.

Many individuals with multicentric Castleman's disease may exhibit an abnormally large liver and spleen (hepatosplenomegaly).

Additionally, Castleman's disease can be divided into categories which are defined by number of anatomic body regions affected by the disease.

In Japan, tocilizumab is also approved for the treatment of Castleman's disease, a rare benign tumor of B cells.

Multicentric Castleman's disease (MCD) involves growths at multiple sites.

Other blood disorders occur in a significant minority of cases, including Castleman's disease, plasmacytoma and MGUS.

He suggested that in patients with normal IL-6 level may present with non-iron deficient type and may resolve after effective treatment of Castleman's disease.

Siltuximab has been investigated for the treatment of metastatic renal cell cancer, prostate cancer, and Castleman's disease, among other types of cancer.

Glomeruloid hemangioma is a distinctive vascular neoplasm first described in 1990 when found to be associated with Crow-Fukase syndrome and Castleman's disease.

There are two main types of Castleman's disease that are determined by the microscopic appearance of the lymph node: hyaline-vascular type and plasma cell type.

He has developed anti-IL6 receptor therapy for several immune disorders including Castleman's disease, rheumatoid arthritis and juvenile idiopathic arthritis.

HHV-8 causes all cases of Kaposi's sarcoma, and has been found in some cases of a cancer-related condition called Castleman's disease.

Plasma cell variant of Castleman's disease - associated with HHV-8 infection and HIV infection.

However, in 2011, Weng et al. described a patient with unicentric Castleman's disease, hyaline vascular type, presenting with severe chronic non-iron-deficient anemia.

This virus causes Kaposi's sarcoma, a cancer commonly occurring in AIDS patients, as well as primary effusion lymphoma and some types of multicentric Castleman's disease.

It has undergone a phase I clinical trial in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.

Unicentric Castleman's disease affects lymph nodes in only one part of the body, while multicentric Castleman's disease affects multiple parts of the body.